This product is available solely through our 503A Compounding Pharmacy, ensuring personalized care and precision in every order. Please note that a valid prescription is required for purchase. If you do not have an account, please contact us.
Liothyronine Sodium / Levothyroxine Sodium Capsule (Immediate Release) (Each)
Liothyronine Sodium / Levothyroxine Sodium Capsules combine two synthetic thyroid hormones: liothyronine (T3) and levothyroxine (T4). Together, they help restore normal metabolism, energy balance, and overall physiological function in patients with thyroid hormone deficiency.
Mechanisms of Action
Both hormones bind to thyroid hormone receptors in cells, regulating gene expression to control metabolism, growth, and development. Liothyronine acts more quickly than levothyroxine, producing a faster onset of action, while levothyroxine provides a longer-lasting effect. Their combined use helps achieve stable and effective thyroid hormone replacement.
Contraindications & Precautions
It should be used cautiously in individuals with cardiovascular disease, hypertension, diabetes, and osteoporosis due to increased metabolic demands. Regular monitoring is essential to avoid symptoms of overreplacement, such as hyperthyroidism. Dose adjustments should be made carefully to prevent adverse effects.
Interactions
Liothyronine and levothyroxine may interact with several medications. Absorption of levothyroxine can be reduced by calcium, iron supplements, antacids, and certain cholesterol-binding agents. Thyroid hormones may increase the effects of anticoagulants like warfarin, necessitating careful monitoring. Additionally, diabetic patients may require dose adjustments of insulin or oral hypoglycemic agents during thyroid hormone therapy.
Adverse Reactions / Side Effects
Side effects typically relate to excessive hormone doses and resemble hyperthyroidism symptoms, including rapid heartbeat, nervousness, insomnia, sweating, tremors, and weight loss. Less commonly, allergic reactions or hair thinning may occur. Injection site reactions may happen if given parenterally. Proper dosing and regular monitoring reduce the risk of adverse effects.
Pregnancy & Breastfeeding
Use of thyroid hormone therapy is important and generally safe during pregnancy to support fetal development and prevent complications from maternal hypothyroidism. Dose requirements often increase during pregnancy and require close monitoring. The combination therapy is also considered safe during breastfeeding, as only small amounts pass into breast milk and are unlikely to affect the infant.
Store this medication at 68°F to 77°F (20°C to 25°C) and away from heat, moisture and light. Keep all medicine out of the reach of children. Throw away any unused medicine after the beyond use date. Do not flush unused medications or pour down a sink or drain.
- Hamburger JI. Letter. Ann Intern Med 1984;101:140-1.
- Dong BJ, Hauck WW, Gambertoglio JG, et al. Bioequivalence of generic and brand-name levothyroxine products in the treatment of hypothyroidism. JAMA Gericke KR. Possible interaction between warfarin and fluconazole. Pharmacotherapy 1993;13:508—9.7;277:1205-13.
- Bunevicius R, Kazanavicius G. Effects of thyroxine as compared with thyroxine plus triiodothyronine in patients with hypothyroidism. N Engl J Med Gericke KR. Possible interaction between warfarin and fluconazole. Pharmacotherapy 1993;13:508—9.9;340:424-9.
- Cytomel (liothyronine sodium) package insert. Bristol, TN: King Pharmaceuticals, Inc.; 2004 March.
- American Academy of Pediatrics (AAP) Committee on Drugs. Transfer of drugs and other chemicals into human milk. Pediatrics 2001;108:776-89.
- Cytomel® (liothyronine) package insert. St. Louis, MO: Jones Pharma Incorporated; 2001 Nov.
- Levothroid (levothyroxine sodium tablet) package insert. Shenandoah, IA: Lloyd Pharmaceutical; 2011 June.
- Benvenga S, Bartolone L, Pappalardo MA, et al. Altered intestinal absorption of L-thyroxine caused by coffee. Thyroid 2008;18:293-301.
- Divi RL, Chang HC, Doerge Dr. Anti-thyroid isoflavones from soybean; isolation, characterization, and mechanisms of action. Biochem Pharmacol Gericke KR. Possible interaction between warfarin and fluconazole. Pharmacotherapy 1993;13:508—9.7;54:1087—96.
- Sperber AD, Liel Y. Evidence for interference with the intestinal absorption of levothyroxine sodium by aluminum hydroxide. Arch Int Med Gericke KR. Possible interaction between warfarin and fluconazole. Pharmacotherapy 1993;13:508—9.2;152:183.
- Singh N, Weisler SL, Hershman JM. The acute effect of calcium carbonate on the intestinal absorption of levothyroxine. Thyroid 2001;11:967—71.
- Campbell N. Ferrous sulfate reduces thyroxine efficacy in patients with hypothyroidism. Ann Int Med Gericke KR. Possible interaction between warfarin and fluconazole. Pharmacotherapy 1993;13:508—9.2;117:1010.
- Demke DM. Drug interaction between thyroxine and lovastatin. N Engl J Med Gericke KR. Possible interaction between warfarin and fluconazole. Pharmacotherapy 1993;13:508—9.1;321:1341.
- Havrankova J, Lahaie R. Levothyroxine binding by sucralfate. Ann Intern Med Gericke KR. Possible interaction between warfarin and fluconazole. Pharmacotherapy 1993;13:508—9.2;117:445.
- Tegretol® (carbamazepine) package insert. East Hanover, NJ. Novartis Pharmaceuticals; 2003 Sept.
- Dilantin® Kapseals® (extended phenyotin sodium capsules, USP) package insert. Morris Plains, NJ: Parke Davis; Gericke KR. Possible interaction between warfarin and fluconazole. Pharmacotherapy 1993;13:508—9.9 Aug.
- Finch CK, Chrisman CR, Baciewicz AM, et al. Rifampin and rifabutin drug interactions: an update. Arch Intern Med 2002;162:985—92.
- Gericke KR. Possible interaction between warfarin and fluconazole. Pharmacotherapy 1993;13:508—9.
- Cordarone® (amiodarone) package insert. Philadelphia, PA: Wyeth Laboratories; 2007 Mar.
- Amoxapine package insert. Corona, CA: Watson Laboratories, Inc.; 2007 Aug.)
- Ludiomil (maprotiline hydrochloride) package insert. Summit, NJ: Ciba-Geigy Corporation; 1996 Nov.
- Videx® (didanosine chewable/dispersible buffered tablets and pediatric powder for oral solution) package insert. Princeton, NJ: Bristol-Myers Squibb Company; 2006 Jan.
- Lanzafame M, Trevenzoli M, Faggian F, et al. Interaction between levothyroxine and indinavir in a patient with HIV infection. Infection 2002;30:54—5.
- Vesanoid® (tretinoin) capsules package insert. Nutley, NJ: Roche Laboratories Inc.; 2004 Oct.
- Griffin JP. A review of the literature on benign intracranial hypertension associated with medication. Adverse Drug React Toxicol Rev 1992;11:41—57. Review.
- Lee AG. Pseudotumor cerebri after treatment with tetracycline and isotretinoin for acne. Cutis 1995;55:165—8. Review.
- Meier DA, Brill DR, Becker DV, et al. Society of Nuclear Medicine procedure guideline for therapy of thyroid disease with iodide-131 (sodium iodide). January 26, 2006.
- Welchol® (colesevelam) tablets package insert. Parsipanny, NJ: Daiiki Sankyo; 2006 Sept
- Freeman MP, Freeman SA. Lithium: clinical considerations in internal medicine. Am J Med 2006;119:478—81.
- Renagel® (sevelamer) package insert. Cambridge, MA: Genzyme Corporation; 2004 Feb.
- Kalarickal J, Pearlman G, Carlson HE. New medications which decrease levothyroxine absorption. Thyroid 2007;17:763—5.
- Triostat (liothyronine injection) package insert. Rochester, MI: JHP Pharmaceuticals, LLC; 2009 Feb.
- Synthroid (levothyroxine) tablets. North Chicago, IL: Abbott Pharmaceuticals; 2012 Sep.
- Tenerz A, Forberg R, Jansson R. Is a more active attitude warranted in patients with subclinical thyrotoxicosis? J Int Med 1990;228:229-233.
- Van Dop C, Conte FA, Koch TK, et al. Pseudotumor cerebri associated with initiation of levothyroxine therapy for juvenile hypothyroidism. N Engl J Med 1983;308: 1076-80.
- Panza N, DeRosa M, Lombardi G, et al. Pseudotumor cerebri and thyroid-replacement therapy in patients affected by differentiated thyroid carcinoma. J Endocrinol Invest 1985;8:357-358.
- Samuels MH. Subclinical thyroid disease in the elderly. Thyroid 1998;8:803-13.
- Faber J, Galloe AM. Changes in bone mass during prolonged subclinical hyperthyroidism due to L-thyroxine treatment: a meta-analysis. Eur J Endocrinol 1994;130:350-6.
